Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

(a) Peripheral blood smear in a patient with ... Low- and High-Grade B-Cell Lymphomas Low-grade lymphomas, including follicular lymphoma and mantle cell lymphoma, frequently harbor BCL2, BCL6 ...